Eli Lilly said in February that it will invest at least $27 billion to build four new manufacturing sites in the U.S. as ...

CEO Dave Ricks said Friday that the company will make its planned GLP-1 weight-loss pill in the U.S. amid President Donald ...

Eli Lilly & Co.'s stock soared 14% Thursday, to put it on track for its biggest one-day gain in about 25 years, after the drugmaker reported positive results from a late-stage trial of a GLP-1 ...

A new daily weight-loss pill, orforglipron, has shown promising results in a trial, with participants losing an average of 16 ...

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for ...

A new weight-loss pill taken daily could compete with injections like Ozempic, research suggests. Patients, who all were ...

The drug helped lower patients’ blood sugar and reduce their weight by an average of 16 pounds.

In the world of wellness and dietary supplements, the focus on natural and effective solutions for weight management and overall health has never been greater. One intriguing product that has emerged ...

Eli Lilly reported promising results from a study of its experimental oral drug that could rival popular injections to treat ...

Lilly shares are up 14.2% in response to the news, while shares of its rivals in the GLP-1 weight loss market, Novo Nordisk ( ...

A daily weight loss pill being tested by Eli Lilly could work as well as its GLP-1 injection counterparts like Ozempic, ...

But this one, for Lilly’s first diabetes and weight-loss pill based on the GLP-1 hormone, was particularly fraught. Days ...